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Abstract
Background: Neoadjuvant chemotherapy has been increasingly practiced on gastric cancer (GC), and histological
evaluation to predict outcome is urgent in clinical practice. There are five classic tumor regression grading (TRG)
systems, including Mandard-TRG system, the Japanese Gastric Cancer Association (JGCA)-TRG system, College of
American Pathologists (CAP)-TRG system, China-TRG system and Becker-TRG system.
Methods: Totally, 192 patients of gastric adenocarcinoma (including adenocarcinoma of the esophagogastric
junction) treated by neoadjuvant chemotherapy and surgery were evaluated using the above five TRG systems. The
clinicopathological characteristics were also assessed. The correlation among TRG systems, clinicopathological
characteristics and prognosis were analyzed.
Results: All the five TRG systems were significantly correlated with differentiation, postsurgical T category,
postsurgical N category, American Joint Committee on Cancer (AJCC) stage, lymph-vascular invasion,
perineural invasion, as well as tumor size. All the five TRG systems were statistically significant in univariate
Cox survival analysis. However, only postsurgical T category, postsurgical N category and R0 resection were
independent in multivariate Cox survival analysis. The tight correlation between the TRG systems and other
characteristics such as postsurgical stage might affect the independent prognostic role of the TRG systems. As
compared with other TRG systems, the hazard ratio of no/slightly response in both Mandard TRG system and
JGCA TRG system revealed higher hazard of death and disease progression than that of severe response
when using univariate Cox survival analysis. The median survival time of complete response and nearly
complete response were much longer than that of partial response, all classified by Mandard-TRG system. This
could help clinicians predict prognosis more reasonably than JGCA-TRG which does not have the category of
nearly complete response.
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Conclusion: We recommend Mandard-TRG system for GC after neoadjuvant chemotherapy due to its better
prediction of prognosis.
Keywords: Gastric cancer, Neoadjuvant chemotherapy, Tumor regression grading
Background
In 2012, 951,000 new diagnoses of gastric cancer
(GC) and 723,000 GC deaths were calculated world-
wide, accounting for 6.8% of all cancer incidence and
8.8% of all cancer mortality, respectively [1]. At
present, GC is the second common cancer in China,
while approximately 679,100 new cancer cases and
498,000 related deaths were estimated in China in
2015 [2]. The most promising curative treatment for
GC is surgical resection. However, this treatment
alone is not enough for curing advanced GC because
of poor long-term outcome, thus a multimodality
therapy is required. Nowadays, neoadjuvant chemo-
therapy has been increasingly used to prolong patient
survival worldwide [3], therefore an effective histo-
pathological evaluation method predicting patient
prognosis is urgently needed in clinical practice. So
far, four tumor regression grading (TRG) systems
were presented by several studies. Mandard et al.
proposed a five-tiered TRG system in esophageal car-
cinoma which has been used widely in digestive ma-
lignancy [4]. The Japanese Gastric Cancer Association
(JGCA) suggested a different five-tiered grading
system specifically for GC [5]. College of American
Pathologists (CAP) recommended a simplified four-
tiered grading system based on Mandard-TRG system
[6]. In China, a three-tiered grading system has been
used for solid malignancies to evaluate the extent of
therapy-related tumor regression [7]. In recent years,
Becker et al. recommended a four-tiered grading sys-
tem for GC based on large number of patients and
long-term follow-up [8, 9]. For the purpose of further
evaluation of the relationship between TRG and
prognosis, we retrospectively collected 192 patients
in our hospital. We used the above five TRG systems
to assess the pathological response respectively, try-




Between January 2007 and August 2013, 192 patients
with locally advanced gastric adenocarcinoma (including
adenocarcinoma of the esophagogastric junction) under-
went gastrectomy in National Cancer Center/Cancer
Hospital, Chinese Academy of Medical Sciences and
Peking Union Medical College. All the patients received
neoadjuvant chemotherapy previously. The treatment
strategies were not uniform, and the drugs most used in-
cluded oxaliplatin, cisplatin, docetaxel, 5-fluorouracil
and Tegafur Gimeracil Oteracil Potassium Capsule.
There were 133 patients who received additional adju-
vant chemotherapy after surgery. All cases had only one
primary gastric tumor, except one patient, who had two
primary lesions located at the fundus and antrum, separ-
ately. The tumor located at the fundus was evaluated in
our study for its relatively higher T category. There were
139 male and 53 female, and the age ranged 31–77 years
old (median age, 55 years old).
Follow-up
The mortality data was mainly gathered from clinical
archives, or via telephone and mail. After treatment,
patients were evaluated every 3 months for the first
2 years, and subsequently every 6 months for the
following 3 years, and then annually according to in-
stitutional policy. Information of recurrence was up-
dated every time the patients came for follow-up
visits. The time of overall-survival (OS) was calculated
from the first day of the neoadjuvant chemotherapy
to the day when death occurred or to the last follow-
up (September 2015). The time of progression-free-
survival (PFS) was calculated from the first day of the
neoadjuvant chemotherapy to the day when progres-
sion happened, death occurred or to the last follow-
up (September 2015). Eleven patients were lost to
follow-up. The median follow-up time was 31 months
(4.1–95.3 months). Three patients, who died as the
result of surgery complications, and 8 patients, whose
follow-up time after surgery were less than 3 months,
were excluded from the survival analysis.
Assessment of the specimens
If obvious residual carcinoma was identified macroscop-
ically, the tumor specimen was sampled for at least 1
block per centimeter. If the maximum of residue was
less than 3 cm or only areas of scar existed, the whole
suspected lesion was submitted completely for histo-
logical examination. Four-micrometer sections were
stained with hematoxylin and eosin. The average of
slides per residual tumor was 9.7 (3–77), while the me-
dian number of the examined lymph nodes per case was
24 (3–58).
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Clinicopathological characteristics
The clinicopathological features include tumor location,
tumor size, histological differentiation, Laurén classifica-
tion, lymph-vascular invasion (LVI) and perineural inva-
sion (PNI). The tumor staging was based on the
American Joint Committee on Cancer (AJCC) cancer
staging 7th edition [10]. All the slides were reviewed by
three experienced pathologists (YZ, JY and LX). In case
of a disagreement about diagnosis, three pathologists
reviewed the slides on a multi-headed microscope and
reached a consensus diagnosis.
Tumor regression grading systems
The criteria of the five TRG systems are shown in
Table 1.
Statistical analysis
Correlations between tumor regression evaluation sys-
tems and clinicopathological characteristics were per-
formed by χ2 tests. And 2-sided p-values < 0.05 were
considered statistically significant. The survival curve
and median survival time were calculated using
Kaplan-Meier method and log rank test. The univariate
analysis of survival was evaluated by univariate Cox
regression analysis. The statistic significant factors in
univariate analysis were assessed by backward step-
wise multivariate Cox regression analysis. Variables
with a p-value of <0.05 were retained, and variables
with a p-value of >0.10 were removed. All statistics




All the 192 patients received radical surgery. Forty-nine
patients underwent proximal subtotal gastrectomy.
Eighty-eight patients underwent distal subtotal gastrec-
tomy. Fifty-three patients underwent total gastrectomy.
Two patients underwent residual gastrectomy, both of
which underwent distal gastrectomy previously due to
severe ulcer. Sixty-three patients underwent D1 lymph-
adenectomy and 129 underwent D2 lymphadenectomy.
The examined numbers of the removed lymph nodes
per case ranged from 3 to 58. One-hundred and fifty-
nine patients got R0 resection (82.8%). Twenty-one
patients had local unresectable residues detected
macroscopically by the surgeons while 12 had micro-
scopically positive margins. Forty-four patients had
Table 1 Criteria of five tumor regression grading systems
TRG system Grade Description
Mandard-TRG 1 No residual cancer
2 Rare residual cancer cells
3 Fibrosis outgrowing residual cancer
4 Residual cancer outgrowing fibrosis
5 Absence of regressive changes
JGCA-TRG 0 No evidence of effect
1a Viable tumor cells occupy more than 2/3 of the tumorous area
1b Viable tumor cells remain in more than 1/3 but less than 2/3 of the tumorous area
2 Viable tumor cells remain in less than 1/3 of the tumorous area
3 No viable tumor cells remain
CAP-TRG 0 No viable cancer cells (complete response)
1 Single cells or small groups of cancer cells (moderate response)
2 Residual cancer outgrown by fibrosis (minimal response)
3 Minimal or no tumor killed or extensive residual cancer (poor response)
China-TRG Severe response Tumor cells completely disappear or very few highly regressive residue exist with obvious
scarring and varying inflammation
Moderate response Most tumor cells degenerate and necrosis with obvious stroma fibrosis and inflammation
Mild response Absence of or slight necrosis and degeneration of tumor cells accompanied by mild stroma
fibrosis and inflammation
Becker-TRG 1a No residual tumor/tumor bed
1b <10% residual tumor/tumor bed
2 10–50% residual tumor/tumor bed
3 >50% residual tumor/tumor bed
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Table 5 Relationships between clinicopathological characteristics and pathological response evaluated by China-TRG system
Characteristics Total cases (n = 192),
no. (%)
China-TRG P value
Severe response (n = 34),
no. (%)
Moderate response (n = 57),
no. (%)
Mild response (n = 101),
no. (%)
Gender 0.063
Male 139 (72.4) 30 (21.6) 41 (29.5) 68 (48.9)
Female 53 (27.6) 4 (7.5) 16 (30.2) 33 (62.3)
Age 0.820
< 55y 89 (46.4) 15 (16.9) 25 (28.1) 49 (55.1)
≥ 55y 103 (53.6) 19 (18.4) 32 (31.1) 52 (50.5)
Location 0.906
Esophagogastric junction 44 (22.9) 6 (13.6) 14 (31.8) 24 (54.5)
Proximal gastric 71 (37) 14 (19.7) 22 (31) 35 (49.3)
Distal gastric 77 (40.1) 14 (18.2) 21 (27.3) 42 (54.5)
Maximal diameter of tumor bed <0.001
< 4.5 cm 108 (56.2) 28 (25.9) 32 (29.6) 48 (44.4)
4.5–8 cm 64 (33.3) 5 (7.8) 21 (32.8) 38 (59.4)
> 8 cm 20 (10.4) 1 (5) 4 (20) 15 (75)
Histological differentiation 0.001
Well-moderate 45 (23.4) 16 (35.6) 12 (26.7) 17 (37.8)
Poor 147 (76.6) 18 (12.2) 45 (30.6) 84 (57.1)
Laurén classification 0.264
Intestinal 77 (40.1) 18 (23.4) 22 (28.6) 37 (48.1)
Diffuse 73 (38) 13 (17.8) 20 (27.4) 40 (54.8)
Mixed 42 (21.9) 3 (7.1) 15 (35.7) 24 (57.1)
LVI <0.001
Negative 94 (49) 30 (31.9) 35 (37.2) 29 (30.9)
Positive 98 (51) 4 (4.1) 22 (22.4) 72 (73.5)
PNI <0.001
Negative 76 (39.6) 33 (43.4) 20 (26.3) 23 (30.3)
Positive 116 (60.4) 1 (0.9) 37 (31.9) 78 (67.2)
AJCC ypT category <0.001
0 11 (5.7) 11 (100) 0 (0) 0 (0)
1 20 (10.4) 12 (60) 5 (25) 3 (15)
2 23 (12) 5 (21.7) 8 (34.8) 10 (43.5)
3 57 (29.7) 5 (8.8) 26 (45.6) 26 (45.6)
4 81 (42.2) 1 (1.2) 18 (22.2) 62 (76.5)
AJCC ypN category <0.001
0 55 (28.6) 22 (40) 18 (32.7) 15 (27.3)
1 36 (18.8) 5 (13.9) 12 (33.3) 19 (52.8)
2 50 (26) 4 (13.9) 19 (38) 27 (54)
3 51 (26.6) 3 (5.9) 8 (15.7) 40 (78.4)
AJCC stage <0.001
0 9 (4.7) 9 (100) 0 (0) 0 (0)
1 24 (12.5) 14 (58.3) 7 (29.2) 3 (12.5)
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adenocarcinoma of the esophagogastric junction (22.9%),
71 had tumors located at proximal stomach (37.0%),
while 77 had tumors located at distal stomach (40.1%).
We used maximal diameter of residual tumor/tumor
bed to describe the size of tumor, which was divided
into three groups [8]: <4.5 cm (n = 108, 56.3%), 4.5–
8 cm (n = 64, 33.3%) and >8 cm (n = 20, 10.4%). The
clinicopathological characteristics were tabulated in
Tables 2, 3, 4, 5 and 6.
Tumor regression assessment
We assessed 192 patients using the five TRG systems re-
spectively. According to Mandard-TRG system, there
were 11 patients in grade 1, 23 in grade 2, 40 in grade 3,
78 in grade 4, and 40 in grade 5. According to JGCA-
TRG system, there were 11 patients in grade 3, 63 in
grade 2, 45 in grade 1b, 33 in grade 1a, and 40 in grade
0. According to CAP-TRG system, there were 11 pa-
tients in grade 0, 23 patients in grade 1, 40 patients in
grade 2, and 118 patients in grade 3. According to
China-TRG system, there were 34 patients in severe re-
sponse grade, 57 in moderate response grade, and 101 in
mild response grade. According to Becker-TRG system,
there were 11 patients in grade 1a, 23 patients in grade
1b, 67 patients in grade 2, and 91 patients in grade 3
(Tables 2, 3, 4, 5 and 6).
Correlation between tumor regression and
clinicopathological features
Tumor regression evaluated by all the five grading
systems has been found significantly associated with
histological differentiation, postsurgical T category, post-
surgical N category, AJCC stage, LVI, PNI and tumor
size (P < 0.05) (Tables 2, 3, 4, 5 and 6).
Survival analysis
One hundred and eighty-one patients were analyzed in
survival analysis. At the final follow-up, 81 patients
(44.8%) were alive with no evidence of recurrence, while
16 (8.8%) were alive with recurrence. Eighty-three
patients (45.9%) had died due to disease recurrence,
while 1 (0.5%) had died of unknown reason excluding
disease recurrence.
All of the five TRG systems, histological differenti-
ation, postsurgical T category, postsurgical N category,
AJCC stage, LVI, PNI, Laurén classification, R0 resection
and tumor size were significant (P < 0.05) correlated with
OS and PFS in univariate Cox regression analyses
(Table 7). The overall and progression-free survival
curves of five TRG systems were present in Figs. 1 and
2, respectively.
Postsurgical T category, postsurgical N category, R0
resection and LVI were independent predictors for OS,
while LVI, postsurgical N category and R0 resection
were independent predictors for PFS, revealed by back-
ward multivariate Cox regression models (Table 8).
None of the five tumor regression grading systems
were found statistically significant in multivariate sur-
vival analysis. In Mandard-TRG system using univari-
ate Cox analysis, the hazard ratio of no response grade
was 3.682 and 4.57 in OS and PFS, respectively. In
JGCA-TRG system using univariate Cox analysis, the
hazard ratio of no response grade was 3.676 and 4.556
in OS and PFS, respectively (Table 7). In the Kaplan-
Meier analysis, the median survival time of OS was
84.4 months for patients with Grade 2 in Mandard-
TRG system, and 57.8 months for those with Grade 2
in JGCA-TRG system (Table 9).
Discussion
Neoadjuvant and adjuvant therapy have been applied to
improve the outcome of localized advanced GC, espe-
cially in east Asia [11]. Preoperative therapy promoted
R0 resection rates in some randomized studies [12]. Al-
though the efficacy of preoperative chemotherapy could
be partially reflected by the Response Evaluation Criteria
in Solid Tumors (RECIST), RECIST is not always con-
sistent with histopathological regression and prognosis.
Thus the relationship among histopathological tumor
regression evaluation, efficiency of the multimodality
Table 5 Relationships between clinicopathological characteristics and pathological response evaluated by China-TRG system
(Continued)
2 53 (27.6) 7 (13.2) 17 (32.1) 29 (54.7)
3 106 (55.2) 4 (3.8) 33 (31.1) 69 (65.1)
R0 resection 0.1
Yes 159 (82.8) 31 (19.5) 49 (30.8) 79 (49.7)
No 33 (17.2) 3 (9.1) 7 (21.2) 23 (69.7)
Adjuvant chemotherapy 0.975
Not received 59 (30.7) 10 (16.9) 17 (28.8) 32 (54.2)
Received 133 (69.3) 24 (18) 39 (29.3) 70 (52.6)
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Table 7 Univariate Cox regression analyses
Characteristics OS PFS
HR 95% CI P value HR 95% CI P value
Gender
Male (reference) 1 1
Female 1.179 0.740–1.876 0.488 1.309 0.859–1.994 0.211
Age
< 55y (reference) 1 1
≥ 55y 1.120 0.903–1.390 0.303 0.856 0.577–1.270 0.441
Location
Esophagogastric junction (reference) 1 1
Proximal gastric 0.952 0.555–1.632 0.857 0.829 0.506–1.358 0.456
Distal gastric 0.634 0.360–1.117 0.115 0.631 0.380–1.046 0.074
Maximal diameter of tumor bed 1.712 1.275–2.299 <0.001 1.709 1.304–2.239 <0.001
Histological differentiation 3.057 1.617–5.782 0.001 2.667 1.513–4.699 0.001
Laurén classification
Intestinal (reference) 1 1
Diffuse 2.228 1.339–3.709 0.002 1.896 1.199–2.999 0.006
Mixed 2.206 1.216–4.003 0.009 1.911 1.113–3.280 0.019
LVI 3.318 2.089–5.270 <0.001 3.324 2.180–5.069 <0.001
PNI 2.878 1.750–4.733 <0.001 2.724 1.737–4.271 <0.001
AJCC ypT category 1.876 1.457–2.415 <0.001 1.739 1.396–2.168 <0.001
AJCC ypN category 1.946 1.572–2.408 <0.001 1.918 1.578–2.330 <0.001
AJCC stage 2.484 1.724–3.580 <0.001 2.270 1.650–3.122 <0.001
Mandard-TRG
1 (reference) 1 1
2 0.98 0.244–3.929 0.977 1.293 0.343–4.877 0.704
3 1.956 0.568–6.730 0.287 2.143 0.631–7.283 0.222
4 2.717 0.836–8.831 0.096 3.155 0.979–10.168 0.054
5 3.682 1.094–12.394 0.035 4.570 1.380–15.132 0.013
JGCA-TRG
3 (reference) 1 1
2 1.531 0.457–5.126 0.49 1.782 0.539–5.892 0.344
1b 2.626 0.781–8.831 0.119 2.621 0.786–8.738 0.117
1a 2.875 0.836–9.884 0.094 4.022 1.199–13.491 0.024
0 3.676 1.092–12.371 0.035 4.556 1.376–15.085 0.013
CAP-TRG
0 (reference) 1 1
1 0.979 0.244–3.927 0.977 1.292 0.343–4.873 0.705
2 1.953 0.568–6.719 0.288 2.140 0.630–7.272 0.223
3 2.996 0.937–9.586 0.064 3.558 1.119–11.311 0.032
China-TRG
Severe response (reference) 1 1
Moderate response 1.719 0.808–3.657 0.160 1.661 0.834–3.308 0.149
Mild response 2.856 1.450–5.628 0.002 2.868 1.544–5.328 0.001
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therapy and prognosis requires further illumination. Glo-
bally, there have been many kinds of histopathological
tumor regression grading systems. Mandard et al. first
published their five-tiered TRG system for esophageal car-
cinoma in 1994. It was reproducible and used widely in
carcinomas of esophagus/esophagogastric junction and
rectum, but there have been no published applications in
GC yet. CAP recommended a simplified four-tiered TRG
system based on Mandard-TRG system. In China, a three-
tiered grading system is used to assess therapeutic re-
sponse for solid malignancies. However, its applicability
on GC remained unclear. Becker et al. proposed a semi-
quantitative four-tiered TRG system in 2003, and then
they proved the applicability on GC in 2011. In Japan, the
wildly used method to evaluate pathological response is
JGCA-TRG, of which the criteria for tumor regression
separation are quite distinct from the other four TRG
systems.
In this study, 118 (61.4%) patients had mild or min-
imal tumor regression. Only 11 (5.7%) cases got
complete regression without any residual tumor cells
on the primary sites, but unfortunately 2 of them
were found with residual lymph nodes metastasis,
probably resulting in poor outcomes. Twenty-three
(12.0%) patients had nearly complete regression with
a few residual tumor cells. We supposed the patients
Table 7 Univariate Cox regression analyses (Continued)
Becker-TRG
1a (reference) 1 1
1b 0.980 0.244–3.927 0.977 1.292 0.343–4.872 0.705
2 2.216 0.673–7.294 0.190 2.295 0.702–7.502 0.169
3 3.109 0.964–10.028 0.058 3.964 1.239–12.681 0.020
R0 resection
Yes (reference) 1 1
No 3.382 2.022–5.659 <0.001 3.656 2.315–5.774 <0.001
Adjuvant chemotherapy
Not received (reference) 1 1
Received 1.040 0.633–1.707 0.878 1.227 0.774–1.943 0.384
Fig. 1 Overall survival curves of five TRG systems, respectively. a Mandard-TRG, b JGCA-TRG, c CAP-TRG, d China-TRG and e Becker-TRG
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who reached complete response should have a better
prognosis while the patients who reached nearly
complete response should have a worse prognosis.
However the actual results did not confirm this.
Agoston et al. defined pathological complete response
as neither residual primary tumor nor residual lymph
node metastasis existing [13]. They reviewed esopha-
geal adenocarcinoma 93 cases with complete response
and found that adequacy of histological examination
of the tumor bed affected the prognosis. In our study,
the number of tumor blocks ranged from 4 to 53 in
the complete response cases, while the number
ranged from 5 to 77 in the nearly complete response
cases. The fewer blocks of some cases might indicate
potentially insufficient tumor sampling. Meanwhile, in
some other studies which emphasized on adequacy of
gross sampling, the percentage of complete response
in GC ranged from 1.2 to 3.6% [14–16]. Among the
23 nearly complete response cases in our study, only
5 were classified to postsurgical T3 or T4 categories,
while the others were suspected to have earlier T cat-
egories before the preoperative therapy. This could be
supposed to explain the different prognosis between
patients who reached complete response and the pa-
tients who had nearly complete response. It is contro-
versial on whether separating the complete response
from the nearly complete response. Becker et al. sepa-
rated the complete response category from the nearly
complete response category and assessed separately,
however, they combined them for survival analysis [9].
Chirieac et al. demonstrated their TRG system as
an independent predictor on esophageal and esopha-
gogastric junction cancer. They evaluated the residual
tumor semi-quantitatively as 0% residue, 1–50% resi-
due and >50% residue [17]. Becker et al. found the
significance in multivariate analysis on the proportion
Fig. 2 Progression-free survival curves of five TRG systems, respectively. a Mandard-TRG, b JGCA-TRG, c CAP-TRG, d China-TRG and e Becker-TRG
Table 8 Multivariate Cox regression analyses
Characteristics OS PFS
HR 95% CI P value HR 95% CI P value
Histological differentiation - - - 1.662 0.914–3.022 0.096
LVI 1.651 0.976–2.793 0.062 1.766 1.091–2.861 0.021
AJCC ypT category 1.355 1.029–1.784 0.031 - - -
AJCC ypN category 1.487 1.168–1.894 0.001 1.479 1.180–1.855 <0.001
R0 resection 2.386 1.398–4.073 0.001 2.457 1.516–3.985 <0.001
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of residual tumor between <10 and >10% in GC [9].
Both studies were based on large number of patients
and long-term follow-up. On contrary, more studies
did not demonstrate the independent role of TRG for
prognosis. In our univariate survival analysis, all the
five TRG systems showed statistical significance which
was coincident with other studies [12, 14, 18, 19]. We
collected exhaustive clinicopathological characteristics
to establish the reliability of this study. The results
indicated that all the TRG systems tightly correlated
with LVI, postsurgical T and N categories, therefore
the staging status and LVI would affect the statistical
significance of the TRG systems in multivariate sur-
vival analysis. This could elucidate the absence of in-
dependent significance of the TRG systems. As
compared with other grading systems, the hazard ra-
tio of no/slightly response grade in both Mandard-
TRG system and JGCA-TRG system revealed higher
hazard of death and disease progression than that of
severe response grade when using univariate Cox sur-
vival analysis. Furthermore, the main difference be-
tween the two five-tiered TRG systems is whether
separating the category of nearly complete response
from partial response. In Mandard-TRG system, the
category of nearly complete response is separated,
however, in JGCA-TRG system, it is not. Because the
median survival time of patients with nearly complete
response in Mandard-TRG system (84.4 months) was
much longer than those with partial response in
JGCA-TRG (57.8 months) (Table 9), separation of
nearly complete response and partial response cat-
egories in Mandard-TRG system could be more rea-
sonable for prognosis prediction.
Conclusions
This study analyzed five classic TRG systems on GC
after neoadjuvant chemotherapy and revealed the signifi-
cance of all the five TRG systems in univariate survival
analysis. We recommend Mandard-TRG system in GC
evaluation for prediction of survival.
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